Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of 1 of the following: * Chronic lymphocytic leukemia (CLL) * B-cell small lymphocytic leukemia (SLL) * Any marginal zone lymphoma * Grade 1-3A follicular lymphoma * Waldenstrom's macroglobulinemia * Mantle cell lymphoma * No transformed indolent lymphoma * Assessable disease (phase I) * Measurable disease (phase I and II), defined as ≥ one lesion that can be accurately measured in ≥ 1 dimension as ≥ 2 cm by conventional techniques OR ≥ 1 cm by spiral CT scan * Lymph nodes measuring ≤ 1 cm in the short axis are considered normal * Relapsed or refractory disease * Must have received at least 1 prior therapeutic regimen but no more than 3 prior conventional cytotoxic therapy regimens * No known brain metastases or meningeal disease PATIENT CHARACTERISTICS: * Karnofsky performance status \> 50% * Absolute neutrophil count \> 1,000/mcl (more than 500/mcl if known lymphomatous involvement) * Platelet count ≥ 50,000/mcl * Total bilirubin \< 1.5 times upper limit of normal (ULN) (less than 5 mg/dL if known history of Gilbert's disease) * AST and ALT ≤ 2.5 times ULN (4 times ULN if liver involvement) * Creatinine \< 1.5 times ULN OR creatinine clearance \> 50 mL/min * Patients may have febrile episodes up to 38.5ºC without evidence of active infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No New York Heart Association class III or IV congestive heart failure * No uncontrolled intercurrent illness, including any of the following: * Ongoing or active infection * Cerebrovascular accident or transient ischemic attack within 6 months of study entry * Unstable angina pectoris * Cardiac arrhythmia * EKG evidence of acute ischemia * Psychiatric illness/social situations that would limit compliance with study requirements * No uncontrolled hypertension requiring active manipulation of antihypertensive medications * No known or active HIV infection * No history of hypersensitivity to bortezomib, boron, or mannitol * No peripheral neuropathy \> grade 2 * No other malignancy within the past 5 years except curatively treated non life-threatening malignancies, such as cutaneous basal cell or squamous cell carcinoma or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior therapy * Prior stem cell transplantation allowed * Preparative cytoreductive and high-dose therapies considered 1 prior therapy * At least 4 weeks since prior cytotoxic chemotherapy (6 weeks since prior nitrosoureas or mitomycin C) * At least 12 weeks since prior radioimmunotherapy * One prior course comprising tositumomab or ibritumomab tiuxetan allowed * At least 1 week since prior palliative steroids for NHL * No therapeutic monoclonal antibodies (e.g., rituximab, tositumomab, ibritumomab, alemtuzumab, etc.) within 3 months of study entry * Patients treated with monoclonal antibodies within 3 months allowed provided disease progressed on this therapy AND no treatment received 7 days prior to study entry * Seven days since prior rituximab (for patients enrolled in phase I portion) * No major surgery within 4 weeks of study entry * No other concurrent investigational agents * No other concurrent anticancer therapy